Why We Don't Default to Skin Substitutes

What the 2027 Medicare Fee Schedule Means for Skin Substitutes

Medicare's 2027 Physician Fee Schedule, finalized in November 2026, keeps skin substitute payment where it landed last year: a flat national rate of $127.14 per square centimeter. It's the second straight year at that rate, and CMS made no change to how the rate is calculated.

That is a long way from where payment stood two years ago. Until 2026, Medicare paid for most skin substitutes based on prices manufacturers reported, and CMS says some products reached more than $2,000 per square centimeter.

For wound care companies built around grafts, the new rate forced a hard reset. For Wound Care Specialists, it changed very little. We never built our practice around skin substitutes, so a lower, steadier rate doesn't change how we treat a single patient. A skin substitute still goes on a wound when the wound is ready for it.

"A lower rate doesn't change a single treatment decision we make," said Dr. Lonnie Lassiter, founder and CEO of the Woud Care Specialists. "We order a skin substitute when the wound bed is ready for one. That's how I've practiced for more than two decades, and the payment rate has never been part of that decision."

Why Facilities Are Wary of Skin Substitutes

The wound care industry has gone through a massive shift over the past year after dealing with its grafting, or skin substitute, problem. Federal prosecutors spent the last couple of years charging companies and clinicians accused of billing Medicare billions of dollars for skin substitutes patients didn't need.

That history is real, and it's why so many facilities today may flinch when a wound care provider walks in their door.

What got lost in all of it is that skin substitutes actually work. They have a real role in wound care when they're used on the right wound at the right time. The product was never the problem. The problem was practices that skipped the diagnosis and went straight to the highest-paying treatment.

Dr. Lassiter, author of the Textbook of Wound Medicine, built our practice on one rule: figure out why the wound stalled before you decide how to treat it.

This article explains how we make that call: what a skin substitute actually does, why some companies reached for grafts first, what happens when a graft goes on an undiagnosed wound, and the specific conditions that have to be true before we order one.

What Is a Skin Substitute and What Is It Supposed to Do?

A skin substitute is a cellular or tissue-based product placed on a wound bed to support closure. Some are made from donated human tissue, some from animal or fish tissue, some from synthetic materials. All of them do one job: give a healing wound scaffolding to build on. None of them diagnose anything.

That last sentence matters more than the definitions. A skin substitute cannot find blocked arteries. It cannot fix low protein. It cannot take pressure off a heel.

In the Lassiter Phases of Wound Healing, most skin substitutes belong to the Building phase. A wound has to finish the Cleaning phase before a graft has any chance: dead tissue out, infection controlled, blood flow confirmed. Put a graft on before that work is done and you have paid for scaffolding on a condemned lot.

Why Did Some Wound Care Companies Apply Grafts to Almost Everything?

Reimbursement. That incentive has mostly gone away since Medicare overhauled how it pays for these products, but it shaped the industry for years.

Until 2026, Medicare paid for most skin substitutes at 106% of each product's average sales price, a number the manufacturers themselves reported. A single application could pay more than months of physician visits. In a 2025 report, the HHS Office of Inspector General found that Medicare Part B spent more than $10 billion on skin substitutes in 2024, and concluded that the products "seem particularly vulnerable to questionable billing and fraud schemes." In the Justice Department's 2025 health care fraud takedown, federal prosecutors in Arizona alleged that clinicians applied grafts in the amounts and frequency that sales representatives decided.

Plenty of wound care companies had good clinicians. But for some of them, skin substitutes were the only treatment and the main source of revenue. When a product pays that well, the product becomes the plan.

Medicare's flat rate has pushed wound care companies to compete on patient outcomes instead of a single treatment. Wound Care Specialists was built that way from the start. We diagnose why a wound has stalled, then move it through the Lassiter Phases of Wound Healing to close it in a way that is medically appropriate and financially responsible.

What Happens When a Graft Goes on an Undiagnosed Wound?

It fails. And in a product-driven practice, the failure gets treated with another graft.

The reason is simple biology. A skin substitute is scaffolding, and scaffolding needs a living foundation to build on. If the wound still has dead tissue in it, or infection, or not enough blood flow to feed new cells, the graft has nothing to work with. Whatever stalled the wound in the first place is still there, and it stalls the graft too.

Dr. Lassiter puts it bluntly in the Textbook of Wound Medicine: "Never graft a dirty or ischemic bed. Re-establish Cleaning and flow first." The textbook's rule for sequencing is just as direct: treat the dominant barrier first. "Ischemia before compression. Infection before grafting. Nutrition before biologic therapy."

So when a graft fails, the graft usually wasn't the problem. The wound is telling you something was missed. A practice that answers a failed graft with a second graft, and then a third, is repeating the same unanswered question at full price.

The right response to a failed graft is a workup, not a reorder.

When Is a Skin Substitute the Right Call?

When a wound has done everything else right and still won't finish the job.

That's the honest answer, and it's also the textbook answer. Dr. Lassiter reserves skin substitutes, which the book calls cellular and tissue-based products (CTPs), for wounds that are clean, well perfused and granulating, but stalled. In other words, the foundation work is done. Blood flow is confirmed. Infection is gone. The wound bed is healthy tissue. The body built everything it could and needs help crossing the finish line.

Before we order one, five things have to be true.

1. The diagnosis is confirmed, including the reason the wound stalled in the first place, because a graft can't fix a cause nobody found.
2. Blood flow has been assessed and it's adequate, since new tissue starves without supply.
3. Infection is cleared and dead tissue is gone. As the textbook puts it, "Biologic products succeed only in a clean, perfused bed."
4. Offloading or compression is in place and working, because the force that created the wound has to stop before anything can rebuild.
5. The wound's progress has been measured over time. Under the textbook's 4-Week Rule, a wound that hasn't shrunk by at least 40% after four weeks of phase-appropriate care needs a full reassessment, not a new product.

This sequence also happens to be the fiscally responsible one, and we're comfortable saying so.

Compression wraps or stockings cost a fraction of a single skin substitute application, which can still run into the thousands of dollars for a larger wound.

If compression heals the wound, the patient got a faster, simpler outcome. The health care system, which means all of us, kept the expensive tool on the shelf for a wound that genuinely needs it.

As Dr. Lassiter writes in the textbook, "prevention remains the most cost-effective intervention, outpacing even the best biologic rescue."

None of this means we're stingy with grafts. When a wound meets the criteria, ordering one is the right medicine and we do it without hesitation. Withholding a needed graft to save money would be the same mistake as placing an unneeded one to make money. The wound decides. That's the whole system.

What We Do Instead: Diagnosis Before Product

Every stalled wound we take on gets a Healing Compass workup. It asks three questions from Dr. Lassiter's Textbook of Wound Medicine:

1. Where is this wound biologically: Cleaning, Building or Closing?
2. Why can't this body heal efficiently?
3. Why does this wound stay open?

The answers name the wound's phase and its healing impairment factors, and those become the treatment plan. Sometimes that plan eventually includes a graft. But it always starts with the reason the wound stalled.

Dr. Lassiter describes the goal as moving "beyond product-centric care and toward true healing." That's the practice we built.

You can also download our one-page brief on this philosophy: Why We're Not Graft-Dependent.

Frequently Asked Questions

Are skin grafts necessary for wound healing?

Usually not. Many wounds close once the underlying cause is diagnosed and treated. Grafts are for the wounds that stall despite that.

Why isn't a wound healing after a skin graft?

Most often because the reason the wound stalled was never found or treated. A graft placed over poor blood flow, infection, pressure or untreated vein disease fails along with the wound.

How many skin graft applications is too many?

The 4-Week Rule in the Textbook of Wound Medicine says a wound that hasn't shrunk at least 40% after four weeks of phase-appropriate care needs a full reassessment. Repeat applications past that point without one mean the plan has stopped responding to the wound. Medicare's rules also vary by region. Some regional Medicare contractors cap skin substitute applications at 10 per wound in a 12-week period, and others review each claim case by case.

What should be done before applying a skin substitute?

Confirm the diagnosis, verify blood flow, clear infection, remove dead tissue, and put offloading or compression in place. Every step should be visible in the chart. Regional Medicare policies that cover skin substitutes expect at least four weeks of documented standard wound care first, and every claim has to show medical necessity.

Get the Diagnosis Before the Next Graft

Patients and families: if a wound isn't closing, something was missed. Request an evaluation and our team will look for it before anything else goes on that wound.

Referral partners: send us your stalled wound histories. We'll do the workup the chart is missing and tell you what we find.